title: [Neuroendocrine neoplasms of the breast].
abstract: Neuroendocrine neoplasms (NEN) of the breast are specific tumor entities. According to the literature up to 5% of breast neoplasms are malignant epithelial neoplasms of the breast. They are defined by a neuroendocrine (NE) architecture and cytology combined with an expression of the neuroendocrine vesicle markers chromogranin A and/or synaptophysin. The diagnosis is supplemented by the receptor status and the proliferative activity. According to the World Health Organization (WHO) classification of 2012 the following groups of NEN are distinguished: (1) invasive breast carcinoma with NE differentiation, (2) well-differentiated neuroendocrine tumor (NET) and (3) poorly differentiated small cell carcinoma (NEC). This review article focuses on (1) the definition and basic principles of diagnostics, (2) the history, nomenclature and WHO classification from 2003 and 2012, (3) the frequency of breast NEN, (4) the hereditary background and functional activity, (5) the expression of receptors and (6) the possible clinical implications. In addition, the first results of a retrospective single center study (n = 465 patients with breast cancer over a time period of 4 years) on the frequency of NEN of the breast at the Breast Center of the University Hospital Düsseldorf are presented. In this study a frequency of 4.5% of NEN was found based on a diagnostic cut-off of > 50% Chromogranin A and/or synaptophysin positive tumor cells.
authors.affiliation: Überregionale Gemeinschaftspraxis Gießen/Limburg/Wetzlar, Institut für Pathologie und Zytologie, St. Vincenz Krankenhaus, 65549, Limburg, Deutschland, anlauf@patho-limburg.de.
authors.forename: M
authors.initials: M
authors.lastname: Anlauf
authors.forename: M
authors.initials: M
authors.lastname: Neumann
authors.forename: S
authors.initials: S
authors.lastname: Bomberg
authors.forename: K
authors.initials: K
authors.lastname: Luczak
authors.forename: S
authors.initials: S
authors.lastname: Heikaus
authors.forename: C
authors.initials: C
authors.lastname: Gustmann
authors.forename: C
authors.initials: C
authors.lastname: Antke
authors.forename: S
authors.initials: S
authors.lastname: Ezziddin
authors.forename: C
authors.initials: C
authors.lastname: Fottner
authors.forename: M
authors.initials: M
authors.lastname: Pavel
authors.forename: U-F
authors.initials: UF
authors.lastname: Pape
authors.forename: A
authors.initials: A
authors.lastname: Rinke
authors.forename: H
authors.initials: H
authors.lastname: Lahner
authors.forename: M
authors.initials: M
authors.lastname: Schott
authors.forename: B
authors.initials: B
authors.lastname: Cremer
authors.forename: D
authors.initials: D
authors.lastname: Hörsch
authors.forename: R P
authors.initials: RP
authors.lastname: Baum
authors.forename: U
authors.initials: U
authors.lastname: Groh
authors.forename: I
authors.initials: I
authors.lastname: Alkatout
authors.forename: C
authors.initials: C
authors.lastname: Rudlowski
authors.forename: P
authors.initials: P
authors.lastname: Scheler
authors.forename: T K
authors.initials: TK
authors.lastname: Zirbes
authors.forename: J
authors.initials: J
authors.lastname: Hoffmann
authors.forename: T
authors.initials: T
authors.lastname: Fehm
authors.forename: H E
authors.initials: HE
authors.lastname: Gabbert
authors.forename: S E
authors.initials: SE
authors.lastname: Baldus
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology*; D049109:Cell Proliferation; D053379:Chromogranin A / Q000032:analysis; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D018358:Neuroendocrine Tumors / Q000473:pathology*; D011379:Prognosis; D016708:Synaptophysin / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A; D016708:Synaptophysin